The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of JRVR, SAVA and SPPI

NEW YORK, NY / ACCESSWIRE / September 6, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

James River Group Holdings, Ltd. (NASDAQ:JRVR)
Class Period: August 1, 2019 - May 5, 2021
Lead Plaintiff Deadline: September 7, 2021

The complaint alleges that during the class period James River Group Holdings, Ltd. made materially false and/or misleading statements and/or failed to disclose that: (1) James River had not adequately reserved for its Uber policies; (2) James River was using an incorrect methodology for setting reserves that materially understated the Company's true exposure to Uber claims; (3) as a result, James River was forced to increase its unfavorable reserves in subsequent quarters even after cancelling the Uber policies; and (4) as a result of the foregoing, Defendants' statements about James River's business, operations, and prospects were materially false and/or misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in JRVR: https://www.kleinstocklaw.com/pslra-1/james-river-group-holdings-ltd-loss-submission-form?id=19404&from=1

Cassava Sciences, Inc. (NASDAQ:SAVA)
Class Period: February 2, 2021 - August 24, 2021
Lead Plaintiff Deadline: October 26, 2021

Throughout the class period, Cassava Sciences, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in SAVA: https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19404&from=1

Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI)
Class Period: December 27, 2018 - August 5, 2021
Lead Plaintiff Deadline: November 1, 2021

According to the complaint, Spectrum Pharmaceuticals, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) the ROLONTIS, an investigational granulocyte-colony stimulating factor analog, manufacturing facility maintained deficient controls and/or procedures; (ii) the foregoing deficiencies decreased the likelihood that the Food and Drug Administration would approve the ROLONTIS biologics license application ("BLA") in its current form; (iii) Spectrum had therefore materially overstated the ROLONTIS BLA's approval prospects; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in SPPI: https://www.kleinstocklaw.com/pslra-1/spectrum-pharmaceuticals-inc-loss-submission-form?id=19404&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm